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S U M M A R Y
The impact of routine rotavirus vaccination on community-acquired (CA) and healthcare-
associated (HA) rotavirus gastroenteritis (RVGE) at a large paediatric hospital, UK, was
investigated over a 13-year period. A total of 1644 hospitalized children aged 0e15 years
tested positive for rotavirus between July 2002 and June 2015. Interrupted time-series
analysis demonstrated that, post vaccine introduction (July 2013 to June 2015), CA- and
HA-RVGE hospitalizations were 83% [95% confidence interval (CI): 72e90%) and 83% (95%
CI: 66e92%] lower than expected, respectively. Rotavirus vaccination has rapidly reduced
the hospital rotavirus disease burden among both CA- and HA-RVGE cases.
ª 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
Introduction
Prior to the introduction of routine vaccination, rotavirus
was the most frequent cause of severe gastroenteritis in chil-
dren aged <5 years worldwide.1 In the UK, rotavirus gastro-
enteritis (RVGE) was estimated to be responsible for 45% and
20% of acute gastroenteritis hospitalizations and emergency
department attendances in children aged <5 years, respec-
tively.2 Rotavirus is also an important cause of healthcare-
associated (HA) gastroenteritis; among children at a large
paediatric hospital, UK, rotavirus was detected by reverse
transcriptionepolymerase chain reaction (RTePCR) in 43% of
community-acquired (CA) and in 31% of HA gastroenteritis
cases.3
Several European countries have introduced rotavirus vac-
cine into their childhood immunization programmes, with
effectiveness against RVGE hospitalizations estimated at
>80%.4 In July 2013 the UK introduced the live-attenuated,
two-dose oral monovalent rotavirus vaccine (Rotarix, Glaxo-
SmithKline Biologicals S.A., Rixensart, Belgium) with doses
given at two and three months of age.5 Vaccine uptake for a
completed course reached 89% by June 2015.6 Early impact
studies in the UK suggested a large reduction (77%) in
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laboratory-confirmed rotavirus infections in vaccine age-
eligible infants.7 However, no impact on HA infection has yet
been described. Understanding the impact of rotavirus vacci-
nation on both CA- and HA-RVGE cases may have implications
for both hospital infection control and bed management pol-
icies, and will help inform the evidence base for continued
immunization in the UK.
This retrospective investigation aimed to quantify the
impact of rotavirus vaccination on HA- and CA-RVGE cases at
the same children’s hospital as our prospectively conducted
study from the pre-vaccine period.3
Methods
Study setting
The study was conducted at Alder Hey Children’s NHS
Foundation Trust, Liverpool, UK (Alder Hey). Alder Hey pro-
vides primary, secondary, and tertiary care facilities for
>200,000 children each year and has w240 inpatient beds.
General medicine, general surgery, and a range of specialist
services including critical care, oncology, cardiology, and
neurosurgery are provided; there is also a large emergency
department.
Case definition
Children aged between 0 and 15 years who were admitted
with RVGE between July 2002 and June 2015, or those in whom
RVGE developed after hospitalization, were eligible for inclu-
sion. Testing for rotavirus was conducted on clinician request
throughout the study period with no age restriction. RVGE was
defined as rotavirus antigen detected by immunochromato-
graphic test or by enzyme immunoassay in a faecal specimen of
a child with acute gastroenteritis. RVGE was considered HA if
gastroenteritis developed 48 h after admission and there was
no record of diarrhoea or vomiting on admission. Clinical and
anonymized demographic data were collected for each
participant, and included information on specimen date,
admission date, age, and symptoms on admission. The pre-
vaccine period was defined as July 2002 to June 2013 and the
vaccine period was defined as July 2013 to June 2015.
Statistical analysis
To assess the impact of rotavirus vaccination on hospitaliza-
tions for CA- and HA-RVGE, an interrupted time-series method-
ology was used. First, monthly expected incidence of rotavirus
hospitalizations was estimated by fitting a negative binomial
regression model to pre-vaccine monthly incidence data, offset
for total monthly admissions and adjusting for seasonality and
secular trends using calendar month and rotavirus year (July to
June), respectively.8 This model was used to predict the coun-
terfactual numbers of RVGE hospitalizations (in the absence of
vaccination) for the vaccine period, where the impact of
vaccination is expressed by the difference between the coun-
terfactual expectation and observed number of hospitaliza-
tions. To quantify change in the number of RVGEhospitalizations
by the introduction of the vaccine, a second model included a
derived binary indicator variable for the post-vaccine period,
enabling the computation of risk ratios (RR) and associated 95%
confidence intervals (CI). This second model offset for total
monthly admissions and adjusted for month and rotavirus year.
Percentage change in incidencewas calculated as 100(1 RR).
The analysis was undertaken separately for CA- and HA-RVGE
hospitalizations. To investigate the impact of routine vaccina-
tion on different age groups the analysis stratified overall RVGE
hospitalizations by age group (<2 years and 2e4 years).
Demographic and clinical characteristics were compared
between RVGE cases from the pre- and post-vaccine periods
and between CA- and HA-RVGE cases. Continuous variables
were tested by Student’s t-test or Wilcoxon rank-sum test if not
normally distributed and c2-test or Fisher’s exact test for
categorical variables. All data handling and statistical analyses
were performed using R Version 3.1.2 (R Development Core
Team, Vienna, Austria).
Ethical approval
Ethical approval was provided by NHS Research Ethics
Committee, South Central-Berkshire (Reference: 14/SC/1140).
Table I
Rotavirus gastroenteritis (RVGE) hospitalizations at Alder Hey among children 0e15 years of age, pre and post rotavirus vaccine
introduction
Variable Yearly mean no. of
hospitalizations (range)
pre vaccine introduction,
July 2002 to June 2013a
No. of hospitalizations post
vaccine introduction,
July 2013 to June 2015
Risk ratio (95% CI) Percentage decline in
hospitalizations (95% CI)b
P-value
Year 1 Year 2
Overall 145 (109e191) 22 30 0.18 (0.11e0.30) 82 (70e89) <0.001
Age (years)
<2 111 (88e145) 17 16 0.16 (0.10e0.26) 84 (74e90) <0.001
2e4 22 (15e32) 2 13 0.31 (0.14e0.62) 69 (38e86) 0.017
5e15 12 (6e20) 2 1 e e e
CA-RVGE 108 (83e150) 18 19 0.17 (0.10e0.28) 83 (72e90) <0.001
HA-RVGE 37 (18e58) 4 11 0.17 (0.08e0.34) 83 (66e92) <0.001
CI, confidence interval; CA, community-acquired; HA, healthcare-associated.
a Yearly means are based on a rotavirus year running July to June.
b Calculated as 1 e (risk ratio). Risk ratio was calculated using a negative binomial model adjusting for calendar month and rotavirus year.
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Results
A total of 1644 hospitalized cases of RVGE were documented
between July 2002 and June 2015. CA cases accounted for
74.2% (N ¼ 1220) of all RVGE cases, 25.4% (N ¼ 418) cases were
HA-RVGE, and 0.4% (N ¼ 6) did not meet the case definition for
either HA or CA. In the pre-vaccine period there was a mean of
145 RVGE hospitalizations per year (range: 109e191),
comprising 108 (83e150) CA and 37 (18e58) HA cases (Table I).
In the first post-vaccine year (July 2013 to June 2014) there
were 22 RVGE cases and in the subsequent year (July 2014 to
June 2015) there were 30 RVGE cases. In the pre-vaccine period
25% (range: 15e35%) of RVGE cases were classified as HA
compared with 29% (18% in 2013/14; 37% in 2014/15) in the
vaccine period (P ¼ 0.6).
There was an estimated 82% reduction in RVGE hospital-
izations (95% CI: 70e89%) in the vaccine period, compared with
what would have been expected in the absence of vaccination
(Table I; Figure 1). Most of the decline occurred in vaccine-
eligible children aged <2 years (84%; 95% CI: 74e90%). A
reduction of 69% (95% CI: 38e86%) was observed in children
aged 2e4 years who were too old to have been vaccinated.
There was an insufficient number of RVGE hospitalizations in
children aged >5 years in the pre-vaccine era (mean per year:
12; range: 6e20) to enable fitting of the regression model
(Table I). The magnitude of reduction in hospitalizations in the
vaccine period was similar in both CA-RVGE (83%; 95% CI:
72e90%) and HA-RVGE (83%; 95% CI: 66e92%) cases (Table I;
Figure 1).
The median age of pre-vaccine CA-RVGE cases [12 months;
interquartile range (IQR): 7e23] was lower than the age of CA-
RVGE cases from the vaccine period (23 months, IQR): 14e26;
P < 0.001). The median age of HA-RVGE cases that occurred in
the pre-vaccine period (nine months; IQR: 4e22) was non-
significantly higher than that of HA-RVGE cases in the vaccine
period (five months; IQR: 4e14; P ¼ 0.131). The median age of
CA-RVGE cases in the pre-vaccine period was significantly
higher than that of HA-RVGE cases (P < 0.001), with this age
difference even greater in the vaccine period (P < 0.001).
Discussion
Since the introduction in 2013 of routine rotavirus vaccina-
tion in the UK there has been a significant decline in hospital-
izations for RVGE in this large paediatric hospital. The
magnitude of reduction was similar for both CA- and HA-RVGE
cases. Age-stratified analysis provided further evidence that
the reduction in hospitalizations is highly likely to be due to the
impact of vaccination as the largest reduction was observed in
vaccine-eligible infants aged <2 years. Furthermore, as shown
in other settings, there was an increase in age of RVGE cases
post vaccine introduction.7,9 The observed reduction in
vaccine-ineligible older age groups (2e4 years) was similar to
that observed through national laboratory surveillance and
may indicate an indirect effect of vaccination.7
We established that HA-RVGE cases were significantly
younger than CA-RVGE cases. Furthermore, an increase in age
in the vaccine period was observed among CA-RVGE cases but
this was not observed among HA-RVGE cases. Similar age pro-
files were also observed at a paediatric hospital in Greece
following vaccine introduction.10 These data suggest that
hospitalized infants aged <1 year remain at risk of developing
HA-RVGE even among highly vaccinated populations, possibly
through direct or indirect exposure to rotavirus from older
children and adults.
Our study relied upon rotavirus antigen testing in stool,
which is known to be a better predictor of symptomatic rota-
virus disease than PCR-based methods; interpretation of a
positive PCR result is rendered difficult because of the high
frequency of asymptomatic rotavirus shedding in young
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Figure 1. Community-acquired (upper graph) and healthcare-associated (lower graph) rotavirus gastroenteritis (RVGE) hospitalizations
at Alder Hey, July 2002 to June 2015. The blue line is the observed incidence of RVGE; the red line is the expected incidence; the grey
shading represents the 95% confidence intervals for the expected incidence. The black hashed line represents the introduction of
rotavirus vaccine in the UK in July 2013.
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children, necessitating the development of a real-time PCR
cut-off to define symptomatic infection.11 Therefore, it is
likely that the cases in this study represent clinical disease.
Although rotavirus vaccination cannot be definitively estab-
lished as the cause of the observed reduction in RVGE hospi-
talizations due to the ecological nature of this study, there are
additional factors suggesting vaccine impact. The reduction in
CA- and HA-RVGE cases in the vaccine period has not been
mirrored by a similar decline in respiratory syncytial virus (RSV)
infection, another viral pathogen that predominately affects
young children in winter; indeed, the incidence of HA-RSV
infection has remained stable whereas RSV infection has
increased in the community (data not shown). There were also
no major changes in hospital infection prevention and control
policies during the period of study. Finally, our study examined
two post-vaccine seasons and took into account long-term
seasonal and annual trends.
This study has demonstrated that, since the introduction of
routine rotavirus vaccination in the UK, in addition to a marked
decline of CA-RVGE cases there has been a similar fall in HA-
RVGE hospitalizations. The reduction in RVGE cases is ex-
pected to save bed-days and reduce the burden on infection
control teams with potential for both clinical and economic
benefit.
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